BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37874822)

  • 1. Interaction of amisulpride with GLUT1 at the blood-brain barrier. Relevance to Alzheimer's disease.
    Boyanova ST; Lloyd-Morris E; Corpe C; Rahman KM; Farag DB; Page LK; Wang H; Fleckney AL; Gatt A; Troakes C; Vizcay-Barrena G; Fleck R; Reeves SJ; Thomas SA
    PLoS One; 2023; 18(10):e0286278. PubMed ID: 37874822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Region-specific blood-brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer's disease.
    Sekhar GN; Fleckney AL; Boyanova ST; Rupawala H; Lo R; Wang H; Farag DB; Rahman KM; Broadstock M; Reeves S; Thomas SA
    Fluids Barriers CNS; 2019 Dec; 16(1):38. PubMed ID: 31842924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of expression and activity of glucose transporters between stem cell-derived brain microvascular endothelial cells and hCMEC/D3 cells.
    Al-Ahmad AJ
    Am J Physiol Cell Physiol; 2017 Oct; 313(4):C421-C429. PubMed ID: 28993322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).
    Do TM; Dodacki A; Alata W; Calon F; Nicolic S; Scherrmann JM; Farinotti R; Bourasset F
    J Alzheimers Dis; 2016; 49(2):287-300. PubMed ID: 26484906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration.
    Winkler EA; Nishida Y; Sagare AP; Rege SV; Bell RD; Perlmutter D; Sengillo JD; Hillman S; Kong P; Nelson AR; Sullivan JS; Zhao Z; Meiselman HJ; Wendy RB; Soto J; Abel ED; Makshanoff J; Zuniga E; De Vivo DC; Zlokovic BV
    Nat Neurosci; 2015 Apr; 18(4):521-530. PubMed ID: 25730668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier.
    Bourasset F; Cisternino S; Temsamani J; Scherrmann JM
    J Neurochem; 2003 Sep; 86(6):1564-7. PubMed ID: 12950465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local perfusion of capillaries reveals disrupted beta-amyloid homeostasis at the blood-brain barrier in Tg2576 murine Alzheimer's model.
    Hanafy AS; Lamprecht A; Dietrich D
    Fluids Barriers CNS; 2023 Nov; 20(1):85. PubMed ID: 37993886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose transporters in brain in health and disease.
    Koepsell H
    Pflugers Arch; 2020 Sep; 472(9):1299-1343. PubMed ID: 32789766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood-brain barrier glucose transporter: effects of hypo- and hyperglycemia revisited.
    Simpson IA; Appel NM; Hokari M; Oki J; Holman GD; Maher F; Koehler-Stec EM; Vannucci SJ; Smith QR
    J Neurochem; 1999 Jan; 72(1):238-47. PubMed ID: 9886075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease.
    Do TM; Alata W; Dodacki A; Traversy MT; Chacun H; Pradier L; Scherrmann JM; Farinotti R; Calon F; Bourasset F
    Neuropharmacology; 2014 Jun; 81():311-7. PubMed ID: 24631967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo upregulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived peptides.
    Boado RJ; Wu D; Windisch M
    Neurosci Res; 1999 Sep; 34(4):217-24. PubMed ID: 10576544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organic cation transporter 1 (OCT1) is involved in pentamidine transport at the human and mouse blood-brain barrier (BBB).
    Sekhar GN; Georgian AR; Sanderson L; Vizcay-Barrena G; Brown RC; Muresan P; Fleck RA; Thomas SA
    PLoS One; 2017; 12(3):e0173474. PubMed ID: 28362799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABC and SLC transporter expression and proton oligopeptide transporter (POT) mediated permeation across the human blood--brain barrier cell line, hCMEC/D3 [corrected].
    Carl SM; Lindley DJ; Das D; Couraud PO; Weksler BB; Romero I; Mowery SA; Knipp GT
    Mol Pharm; 2010 Aug; 7(4):1057-68. PubMed ID: 20524699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abundance of P-Glycoprotein and Other Drug Transporters at the Human Blood-Brain Barrier in Alzheimer's Disease: A Quantitative Targeted Proteomic Study.
    Storelli F; Billington S; Kumar AR; Unadkat JD
    Clin Pharmacol Ther; 2021 Mar; 109(3):667-675. PubMed ID: 32885413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
    Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O
    Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition protects blood-brain barrier P-glycoprotein and lowers Aβ brain levels in an Alzheimer's disease model.
    Vulin M; Zhong Y; Maloney BJ; Bauer B; Hartz AMS
    Fluids Barriers CNS; 2023 Oct; 20(1):70. PubMed ID: 37803468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal chemokine profile expression in a blood-brain barrier model from Alzheimer transgenic versus wild-type mice.
    Vérité J; Janet T; Chassaing D; Fauconneau B; Rabeony H; Page G
    J Neuroinflammation; 2018 Jun; 15(1):182. PubMed ID: 29898739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides.
    Xiong H; Callaghan D; Jones A; Bai J; Rasquinha I; Smith C; Pei K; Walker D; Lue LF; Stanimirovic D; Zhang W
    J Neurosci; 2009 Apr; 29(17):5463-75. PubMed ID: 19403814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier.
    Yu XY; Lin SG; Chen X; Zhou ZW; Liang J; Duan W; Chowbay B; Wen JY; Chan E; Cao J; Li CG; Zhou SF
    Curr Drug Metab; 2007 May; 8(4):365-78. PubMed ID: 17504224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.